Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06361485 · ClinicalTrials.gov registry record · Phase 1

Safety and Feasibility of Umbilical Cord Wharton's Jelly Allograft Injections for Lumbar Pain

A Phase 1 study of Low Back Pain, sponsored by R3 Stem Cell.

Recruiting
Registry status
Phase 1
Development phase
100
Enrollment target
4
Study locations

NCT06361485 is a Phase 1 study of Low Back Pain that is actively recruiting participants, run by R3 Stem Cell. The registered enrollment target is 100 participants, below the 503-participant average among 122 other Low Back Pain trials with a reported enrollment target (80% lower). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06361485, a Phase 1 study of Low Back Pain, is actively recruiting participants, sponsored by R3 Stem Cell.

RECRUITING
Registry status
Phase 1
Development phase
100 participants
Enrollment target
4
Study locations

Study Summary

This is a Pilot Study that is an open label, prospective, non-controlled study in which the safety and feasibility of Wharton's Jelly (WJ) allograft will be evaluated in 100 participants suffering with low back pain.

Conditions Studied

Interventions

  • BIOLOGICAL Lumbar Injections with 10cc's of Wharton's Jelly Allograft

Study Locations (4)

Arizona

  • R3 Anti Aging Scottsdale - Scottsdale

California

  • R3 Anti Aging Beverly Hills - Beverly Hills

New York

  • Scheer Medical Wellness - New York

Texas

  • Dr. Duc (Steve) Le, MD - Cleveland

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2024-03-25
Est. Completion 2028-04-01
Phase Phase 1

Sponsor

R3 Stem Cell

2 total trials

What the Registry Record Tells You About NCT06361485

The ClinicalTrials.gov registry entry for NCT06361485 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 503-participant average among 122 other Low Back Pain trials with a reported enrollment target (80% lower). The listed sponsor is R3 Stem Cell, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Low Back Pain appearing as the primary indexed condition, and to 1 intervention - of which Lumbar Injections with 10cc's of Wharton's Jelly Allograft is the first listed.

NCT06361485 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Arizona, California, New York.

Frequently Asked Questions

What is clinical trial NCT06361485 about?

NCT06361485 is a clinical study titled "Safety and Feasibility of Umbilical Cord Wharton's Jelly Allograft Injections for Lumbar Pain". This is a Pilot Study that is an open label, prospective, non-controlled study in which the safety and feasibility of Wharton's Jelly (WJ) allograft will be evaluated in 100 participants suffering with low back pain.

What is the current status of trial NCT06361485?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2024-03-25. Estimated completion is 2028-04-01.

What conditions does trial NCT06361485 study?

This clinical trial studies the following conditions: Low Back Pain.

What interventions are being tested in trial NCT06361485?

The interventions under investigation include: Lumbar Injections with 10cc's of Wharton's Jelly Allograft (BIOLOGICAL).

Who is sponsoring clinical trial NCT06361485?

This trial is sponsored by R3 Stem Cell, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06361485 being conducted?

This trial has 4 study locations across Arizona, California, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Low Back Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.